A study of the immunosuppressive activity of methylene dimethane sulphonate (MDMS) in relation to its effectiveness as an anti-tumour agent.
The anti-tumour action of methylene dimethane sulphonate (MDMS) has been further investigated in relation to its immunosuppressive properties. Following a dose of 10 mg/kg, the proportion of permanent regressions of Yoshida lymphosarcoma transplants is lower in animals treated during the first 5 days of tumour growth. Re-implants on day 28 to those animals in which regression of the tumour had occurred indicated that the immune response to the tumour increases during the first 7 days of tumour growth.Studies of the effect of MDMS on the primary antibody-forming cell response of mice to sheep red cell antigens showed this drug to be an immunosuppressant comparable in strength to x-radiation. MDMS given to rats prior to tumour transplantation also acted as an immunosuppressant in this system resulting in an increased rate of tumour growth. For both responses the maximum immunosuppressive effect was obtained when the interval between drug administration and antigenic challenge was minimal.
D000818:Animals; D000917:Antibody Formation; D000921:Antibody-Producing Cells / Q000276:immunology; D000941:Antigens; D004912:Erythrocytes / Q000276:immunology; D004952:Esters / Q000627:therapeutic use; D005260:Female; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D051381:Rats; D012517:Sarcoma, Yoshida / Q000188:drug therapy*; D012756:Sheep; D013154:Spleen / Q000276:immunology; D013451:Sulfonic Acids / Q000627:therapeutic use*; D013997:Time Factors
D000941:Antigens; D004952:Esters; D007166:Immunosuppressive Agents; D013451:Sulfonic Acids